Boehringer Ingelheim Reveals Battle Plans For Olmutinib

Boehringer Ingelheim has revealed its Phase III plans for its third-generation EGFR inhibitor, olmutinib, a product that was recently approved in its first market, South Korea, but still faces significant competition in this crowded area.